modelTriamcinolone_1
Extends from Pharmacolibrary.Drugs.ATC.C.C05AA12_1.
Information
| name: | Triamcinolone_1 | |
| ATC code: | C05AA12_1 | route: | topical |
| compartments: | 1 | |
| dosage: | 5 | mg |
| volume of distribution: | 86 | L |
| clearance: | 1.7 | L/h |
| other parameters in model implementation | ||
Triamcinolone is a synthetic corticosteroid with glucocorticoid activity, used for its anti-inflammatory and immunosuppressive effects. It is indicated for various conditions including allergic reactions, dermatological diseases, and as a local treatment for joint inflammation. It is approved and widely used clinically in multiple formulations.
Pharmacokinetics
Estimated pharmacokinetic parameters for triamcinolone administered topically as used under ATC code C05AA12. No direct publications found for topical formulation.
References
Ramadas, AA, et al., & Kumar, SP (2016). Systemic absorption of 0.1% triamcinolone acetonide as topical application in management of oral lichen planus. Indian journal of dental research : official publication of Indian Society for Dental Research 27(3) 230–235. DOI:10.4103/0970-9290.186237 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27411649
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)